Jenny L. Wiley

Jenny L. Wiley

Auto-generated profile, based on publicly available information

Jenny L. Wiley

RTI International, 3040 Cornwallis Road, Research Triangle Park, NC 27709, USA

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JLJonathan Z. Long
Jonathan Z. Long
DNDaniel K. Nomura
Daniel K. Nomura
RVRobert E. Vann
Robert E. Vann
DWD. Matthew Walentiny
D. Matthew Walentiny
LBLamont Booker
Lamont Booker
BCBenjamin F. Cravatt
Benjamin F. Cravatt
Δ9-Tetrahydrocannabinol (THC), the psychoactive component of marijuana, and other direct cannabinoid receptor (CB1) agonists produce a number of neurobehavioral effects in mammals that range from the beneficial (analgesia) to the untoward (abuse potential). Why, however, this full spectrum of activities is not observed upon pharmacological inhibition or genetic deletion of either fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL), enzymes that regulate the two major endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG), respectively, has remained unclear. Here, we describe a selective and efficacious dual FAAH/MAGL inhibitor, JZL195, and show that this agent exhibits broad activity in the tetrad test for CB1 agonism, causing analgesia, hypomotilty, and catalepsy. Comparison of JZL195 to specific FAAH and MAGL inhibitors identified behavioral processes that were regulated by a single endocannabinoid pathway (e.g., hypomotility by the 2-AG/MAGL pathway) and, interestingly, those where disruption of both FAAH and MAGL produced additive effects that were reversed by a CB1 antagonist. Falling into this latter category was drug discrimination behavior, where dual FAAH/MAGL blockade, but not disruption of either FAAH or MAGL alone, produced THC-like responses that were reversed by a CB1 antagonist. These data indicate that AEA and 2-AG signaling pathways interact to regulate specific behavioral processes in vivo, including those relevant to drug abuse, thus providing a potential mechanistic basis for the distinct pharmacological profiles of direct CB1 agonists and inhibitors of individual endocannabinoid degradative enzymes.

1 March 2013 in Life Sciences
Verified
Journal Article
Closed access
RCRebecca M. Craft
Rebecca M. Craft
JMJulie A. Marusich
Julie A. Marusich
JWJenny L. Wiley
Jenny L. Wiley

1 December 1999 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
JHJohn W. Huffman
John W. Huffman
JLJohn Liddle
John Liddle
SYShu Yu
Shu Yu
MAMie Mie Aung
Mie Mie Aung
MAMary Abood
Mary Abood
BMBilly R. Martin
Billy R. Martin

1 January 2005 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
JHJohn W. Huffman
John W. Huffman
GZGulay Zengin
Gulay Zengin
MWMing-Jung Wu
Ming-Jung Wu
JLJianzhong Lu
Jianzhong Lu
GHGeorge Hynd
George Hynd
BMBilly R. Martin
Billy R. Martin

1 September 2001 in European Journal of Pharmacology
Verified
Journal Article
Closed access
MWMelisa J Wallace
Melisa J Wallace
JWJenny L Wiley
Jenny L Wiley
BMBilly R Martin
Billy R Martin
RDRobert J DeLorenzo
Robert J DeLorenzo

1 June 2005 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
JWJenny L Wiley
Jenny L Wiley
JBJames J Burston
James J Burston
DLDarnica C Leggett
Darnica C Leggett
OAOlga O Alekseeva
Olga O Alekseeva
RRRaj K Razdan
Raj K Razdan
BMBilly R Martin
Billy R Martin